A Descriptive Comparative Analysis of Safety Concerns Outlaid in the Risk Management Plans of the European Union and Japan

Bibliographic Details
Main Authors:	Teruyuki Honda, Mamoru Narukawa
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Pharmacoepidemiology and Drug Safety
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Comparison of Prescribing Information for Elderly Patients on Drug Labels in Japan, the United States, and Europe
by: Makoto Onohara, et al.
Published: (2025)

Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations
by: Thomas Goedecke, et al.
Published: (2024)

Unfilled Prescriptions in Japan: A 10‐Year Retrospective Analysis
by: Yuki Kataoka, et al.
Published: (2026)

Safety Assessment of Influenza Vaccination for Neurological Outcomes Among Older Adults in Japan: A Self‐Controlled Case Series Study
by: Mitsunori Ogawa, et al.
Published: (2025)

A European, Observational, 3‐Year Cohort Comparative Study on the Safety of the Fixed Dose Combination Pravastatin 40 mg/Fenofibrate 160 mg vs. Statin Alone in Real Clinical Practice: The POSE Study
by: Nikolaos Papadopoulos, et al.
Published: (2024)

Comparative Safety of Glucagon‐Like Peptide 1 Receptor Agonists ( GLP ‐1‐ RAs ) in Type 2 Diabetes and Chronic Weight Management: A Real‐World Data Study
by: Sarah Ruth Hurwitz, et al.
Published: (2025)

Comparative Effectiveness and Safety of Torsemide Versus Furosemide in Older Adults With Heart Failure
by: Amina A. Alkhalaf, et al.
Published: (2025)

Association of Quinolone Exposure in the First‐Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan
by: Kei Morishita, et al.
Published: (2025)

Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post‐Authorization Safety Survey Among Physicians
by: Angelika Wientzek‐Fleischmann, et al.
Published: (2025)

Comparative Cardiovascular Safety of Prescription Amphetamine and Methylphenidate Initiation Among Older Adult Medicare Beneficiaries
by: Noah Smith, et al.
Published: (2026)

Comparative Safety of Biologic and Targeted‐Synthetic DMARDs in Patients With Rheumatoid Arthritis: A Multi‐Database Real‐World Cohort Study
by: Yinzhu Jin, et al.
Published: (2025)

Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries
by: Sandrine Colas, et al.
Published: (2024)

Impact of Regulatory Risk Communication on Thrombosis With Thrombocytopenia Syndrome for COVID‐19 Adenovirus Vector Vaccines on European Healthcare Professionals
by: Ella van Vliet, et al.
Published: (2024)

Comparative Risk for Neuropsychiatric Events in Leukotriene Receptor Antagonist vs. Inhaled Corticosteroid in Children With Asthma: A Nationwide Observational Study With a Complementary Analysis Using Natural Language Processing
by: Subin Kim, et al.
Published: (2025)

Comment on “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan” by Morishita K. Et Al.
by: Mesut Gungor, et al.
Published: (2025)

Safety and Effectiveness of Apixaban Versus Rivaroxaban in Atrial Fibrillation Patients in Singapore: An Active‐Comparator, New‐User Cohort study
by: Aaron Jun Yi Yap, et al.
Published: (2026)

Opioid Use and the Risk of Ventricular Arrhythmias: A Systematic Review and Meta‐Analysis
by: Shahrzad Salmasi, et al.
Published: (2024)

Use of Machine Learning to Compare Disease Risk Scores and Propensity Scores Across Complex Confounding Scenarios: A Simulation Study
by: Yuchen Guo, et al.
Published: (2025)

Performance of the Self‐Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using the Clinical Practice Research Datalink ( CPRD )
by: Astrid Coste, et al.
Published: (2025)

Performance of the Self‐Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using Merative MarketScan Research Databases
by: Astrid Coste, et al.
Published: (2025)

Performance of the Self‐Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using the French Administrative Healthcare Database ( SNDS )
by: Astrid Coste, et al.
Published: (2025)

Evaluating Data Quality by Proxy: Can We Evaluate All Dimensions of the European Medicines Agency Data Quality Framework for Registry‐Based Post‐Authorization Safety Studies?
by: Pamela Dobay, et al.
Published: (2026)

COVID ‐19 State of Emergency and Biological Therapy Persistence for Ulcerative Colitis: An Interrupted Time Series Study Using a Nationwide Claims Database
by: Mitsuhiro Mori, et al.
Published: (2026)

Efficacy and Safety of All Monoclonal Antibodies in Moderate‐to‐Severe Atopic Dermatitis: A Systematic Review and Network Meta‐Analysis
by: Wenting Cai, et al.
Published: (2025)

A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
by: J. Bradley Layton, et al.
Published: (2025)

PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage
by: Kazuhiro Kajiyama, et al.
Published: (2024)

Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events
by: William Bai, et al.
Published: (2025)

Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register‐Based Time Series Analysis
by: Jarno Rutanen, et al.
Published: (2026)

Titel: Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Treated With Immune Checkpoint Inhibitors Compared to Other Antineoplastic Medications: A Nationwide Study
by: Ida M. Heerfordt, et al.
Published: (2025)

Drug Safety: Being Vigilant… or Proactive?
by: Alain Braillon
Published: (2026)

A Methodological Review of Simulation Studies Published in Pharmacoepidemiology and Drug Safety
by: Ryan Muddiman, et al.
Published: (2026)

Utilization of Oral Contraceptives and Hormone Therapy for Menopause Among Female Individuals With Migraine With Aura: A Descriptive Study
by: Liza R. Gibbs, et al.
Published: (2025)

Agreement of Medication Information Derived From EHR Data Compared to Medicare Insurance Claims: An Analysis of Biologic Disease‐Modifying Antirheumatic Drugs
by: Jing Li, et al.
Published: (2024)

Evaluation of Medication Adherence Among Prevalent Users in Hypertension, Dyslipidemia, and Diabetes Using Health Insurance Claims: A Population‐Based Cohort Study in Japan
by: Minako Matsumoto, et al.
Published: (2024)

A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis‐Related Safety Signals
by: Priscilla O. M. V. Lopes, et al.
Published: (2026)

Performance of the Self‐Controlled Case Series for Drug Safety Signal Detection: A Multi‐Database Study
by: Astrid Coste, et al.
Published: (2026)

Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data
by: Tamino Zappalà, et al.
Published: (2024)

Safety of BNT162b2 mRNA COVID ‐19 Vaccine Batches: A Nationwide Cohort Study
by: Max Schmeling, et al.
Published: (2025)

Strengthening Pharmacoepidemiology in a Changing Research Environment: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance ( ENCePP )
by: Xavier Kurz, et al.
Published: (2025)

Prevalent‐New User Design for Biosimilar Safety Using Saudi Real‐World Data
by: Ohoud Almadani, et al.
Published: (2026)

Similar Items

Similar Items